Business Wire

Clarity AI: Whitewashing the Green Out of Brands Working Towards Transparency in Sustainability Won’t Save the Planet

Share

Clarity AI, the leading global sustainability tech platform, announced today that it believes the positive viral attention Patagonia received last week and the negative viral attention H&M and other fast-fashion brands received over the past few months is clouding the picture of what can actually save the planet.

A few days ago, Yvon Chouinard – the Chairman of Patagonia – announced that he will be donating the entire company, worth $3 billion, to fight climate change. Social networks were on fire sharing the news and supporting Chouinard – CEOs, fashion models, and millions of consumers. The story went viral. Another viral story from earlier this summer is related to fast-fashion giant H&M. It is facing a class-action lawsuit, brought by a student at SUNY New Paltz, for using misleading sustainability claims and for employing the fast-fashion business model while working to be more sustainable.

Around the same time, regulators in Europe bore down on the use of inaccurate data or misleading claims. The Norwegian Consumer Authority (NCA) concluded that H&M’s usage of sustainability data was non-compliant. Then, the UK’s Competitions and Markets Authority opened an investigation to scrutinize the sustainability claims made by 3 brands – ASOS, Boohoo, and Walmart-owned George at Asda. The Netherlands’ Authority for Consumer Markets (ACM) followed and put H&M and Decathlon, the largest sporting goods retailer in the world, under investigation for using misleading “green” claims. And considering 60% of the top 20 fashion conglomerates by market cap have similar sustainability claims, Clarity AI believes this is just the beginning of whitewashing the green out of fashion.

“A very large fast-fashion company can have a globally-sized impact on sustainability. And, in terms of size, H&M is 1.5% of the fashion industry and is more than 15 times bigger than Patagonia,” notes Rebeca Minguela, Founder & CEO, of Clarity AI. “Yes, the fast-fashion model, which is approximately 10% of the fashion industry, generates waste and fuels consumerism, but it is not acceptable to say the entire industry cannot push to be more sustainable or that it is solely to blame for the planet’s woes.”

How does H&M’s size relate to carbon emissions and potential emissions reduction? When looking at the intensity of carbon emissions (CO2 per dollar of revenue), Patagonia performs more than twice as well as H&M. H&M has committed to get to that intensity level by 2030, and it is on track so far. Should it achieve its goal, H&M will be at almost exactly the same level of carbon emissions intensity that Patagonia is today. That would mean that H&M would successfully reduce 56% of their emissions, which is the same as 8 million flights from London to NYC or 21 times Patagonia’s yearly emissions.

“The reality is that advanced technology models actually allow us to improve the data displayed on those labels,” added Ms. Minguela. “We can measure more, and better. We should encourage H&M and the rest of the fashion industry – the other 98.5% – to add those improved sustainability labels and for consumers to use that information.”

About Clarity AI

Clarity AI is a sustainability technology platform that uses machine learning and big data to deliver environmental and social insights to investors, organizations, and consumers. As of August 2022, Clarity AI’s platform analyzes more than 50,000 companies, 300,000 funds, 198 countries and 188 local governments – 2-13 times more than any other player in the market – and delivers data and analytics for investing, corporate research, benchmarking, consumer ecommerce and reporting. Clarity AI has offices in North America, Europe and the Middle East, and its investor client network manages tens of trillions in assets under management. clarity.ai

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact
Julia Wright
Edelman
clarityAI@edelmansmithfield.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye